DE602004027936D1 - Tocopherolmodifizierte therapeutische arzneimittelverbindung - Google Patents

Tocopherolmodifizierte therapeutische arzneimittelverbindung

Info

Publication number
DE602004027936D1
DE602004027936D1 DE602004027936T DE602004027936T DE602004027936D1 DE 602004027936 D1 DE602004027936 D1 DE 602004027936D1 DE 602004027936 T DE602004027936 T DE 602004027936T DE 602004027936 T DE602004027936 T DE 602004027936T DE 602004027936 D1 DE602004027936 D1 DE 602004027936D1
Authority
DE
Germany
Prior art keywords
tocopherol
therapeutic drug
modified therapeutic
compounds
drug compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004027936T
Other languages
German (de)
English (en)
Inventor
Yuehua Zhang
Lynn C Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achieve Life Sciences Inc
Original Assignee
Sonus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sonus Pharmaceuticals Inc filed Critical Sonus Pharmaceuticals Inc
Publication of DE602004027936D1 publication Critical patent/DE602004027936D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602004027936T 2003-10-29 2004-10-29 Tocopherolmodifizierte therapeutische arzneimittelverbindung Expired - Lifetime DE602004027936D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51536403P 2003-10-29 2003-10-29
US55613704P 2004-03-24 2004-03-24
US55876204P 2004-04-01 2004-04-01
US62165504P 2004-10-26 2004-10-26
PCT/US2004/036127 WO2005042539A1 (en) 2003-10-29 2004-10-29 Tocopherol-modified therapeutic drug compounds

Publications (1)

Publication Number Publication Date
DE602004027936D1 true DE602004027936D1 (de) 2010-08-12

Family

ID=34557676

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027936T Expired - Lifetime DE602004027936D1 (de) 2003-10-29 2004-10-29 Tocopherolmodifizierte therapeutische arzneimittelverbindung

Country Status (12)

Country Link
US (3) US7223770B2 (https=)
EP (1) EP1682552B1 (https=)
JP (1) JP2007509978A (https=)
KR (1) KR20060110872A (https=)
AT (1) ATE472551T1 (https=)
AU (1) AU2004285037B2 (https=)
BR (1) BRPI0415858A (https=)
CA (1) CA2543722C (https=)
DE (1) DE602004027936D1 (https=)
IL (1) IL175158A0 (https=)
TW (1) TW200522978A (https=)
WO (1) WO2005042539A1 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
NZ554677A (en) * 2004-11-05 2010-08-27 Samyang Corp Pharmaceutical formulation for increasing solubility of 10-hydroxycamptothecin compounds in non-aqueous polar solvents
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
US20080274195A1 (en) 2005-07-18 2008-11-06 University Of Massachusetts Lowell Compositions and Methods for Making and Using Nanoemulsions
AU2016244292A1 (en) * 2005-07-18 2016-11-03 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
US20090306198A1 (en) * 2005-09-16 2009-12-10 Robert Nicolosi Anti-Oxidant Synergy Formulation Nanoemulsions to Treat Caner
US7572610B2 (en) * 2005-10-03 2009-08-11 Biotechnology Research & Development Corporation Methods of making compositions comprising a UV-Absorbing chromophore
US7744856B2 (en) * 2005-10-03 2010-06-29 Biotech Research And Development Corporation Formulations with feruloyl glycerides and methods of preparation
US7727514B2 (en) * 2005-10-03 2010-06-01 Biotechnology Research & Development Corporation Compositions comprising a UV-absorbing chromophore
KR102110379B1 (ko) 2005-12-01 2020-05-14 유니버시티 오브 메사츄세츠 로웰 보툴리눔 나노에멀젼
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7786134B2 (en) * 2005-12-16 2010-08-31 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds, compositions and related methods
CZ300305B6 (cs) * 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
MX2008016455A (es) * 2006-06-29 2009-05-15 Biotech Res And Dev Corp Formulaciones con feruloil-gliceridos, y metodos de preparacion.
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions
SG179457A1 (en) 2006-12-01 2012-04-27 Anterios Inc Peptide nanoparticles and uses therefor
SG177184A1 (en) 2006-12-01 2012-01-30 Anterios Inc Amphiphilic entity nanoparticles
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
WO2009002425A2 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
EP2222278B1 (en) * 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
BRPI0909185A2 (pt) 2008-03-20 2015-08-25 Virun Inc Derivado de vitamina e e seus usos
PL2268160T3 (pl) 2008-03-20 2013-05-31 Virun Inc Emulsje zawierające pochodną PEG tokoferolu
US7670894B2 (en) * 2008-04-30 2010-03-02 Intel Corporation Selective high-k dielectric film deposition for semiconductor device
KR101848095B1 (ko) * 2008-06-26 2018-04-11 안테리오스, 인코퍼레이티드 경피 운반
US8268786B2 (en) * 2009-04-23 2012-09-18 First Tech International Limited Anti-cancer tocotrienol analogues and associated methods
US9180113B2 (en) * 2009-09-01 2015-11-10 First Tech International Limited Tocotrienol compositions
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8969303B2 (en) * 2010-02-05 2015-03-03 First Tech International Limited Tocotrienol esters
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
CA2792330C (en) * 2010-03-23 2017-01-03 Virun, Inc Nanoemulsion including a peg-derivative of vitamin e and a sucrose fatty acid ester
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
EP2606910B1 (en) * 2010-08-20 2018-10-17 National University Corporation Tokyo Medical and Dental University Pharmaceutical composition for transcolonic absorption
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
CN102516258B (zh) * 2011-11-11 2014-06-25 正大天晴药业集团股份有限公司 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用
US10874122B2 (en) 2012-02-10 2020-12-29 Virun, Inc. Beverage compositions containing non-polar compounds
CN102731518B (zh) * 2012-06-26 2014-12-03 济南精合医药科技有限公司 用于抗肿瘤药物的邻硝基芳甲氧基喜树碱缺氧激活前药
CN102731519B (zh) * 2012-06-26 2014-12-17 济南精合医药科技有限公司 用于抗肿瘤药物的对硝基芳甲氧基喜树碱缺氧激活前药
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US20140314672A1 (en) * 2013-04-06 2014-10-23 Igdrasol, Inc. Nanoparticle therapeutic agents, their formulations, and methods of their use
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
CA2947741A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
WO2015171924A2 (en) * 2014-05-07 2015-11-12 Cornell University Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US9999626B2 (en) 2014-06-18 2018-06-19 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
CA2963819A1 (en) * 2014-10-08 2016-04-14 Epigenetics Pharma Llc Vitamin e-nucleoside prodrugs
CN105777770B (zh) * 2014-12-26 2018-05-25 中国人民解放军第二军医大学 一种饱和长链脂肪酸修饰的7-乙基-10-羟基喜树碱化合物及其长循环脂质体
CN104800858B (zh) * 2015-04-27 2017-11-21 中国医学科学院基础医学研究所 Hsp90抑制肽偶联物及其在肿瘤治疗中的应用
GB2550346B (en) * 2016-05-13 2021-02-24 Phytoceutical Ltd Micelles
ES2827796T3 (es) 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
MX2019005833A (es) 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.
US20200131231A1 (en) 2017-02-17 2020-04-30 Oxford University Innovation Limited Cell penetrating peptides
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
CA3112778A1 (en) 2018-09-17 2020-03-26 The Children's Hospital Of Philadelphia Polymer-based macromolecular prodrugs
US12465646B2 (en) 2018-12-07 2025-11-11 Oxford University Innovation Limited Linkers
KR20220157944A (ko) 2020-02-21 2022-11-29 아카우오스, 인크. 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법
CA3229030A1 (en) * 2021-09-05 2023-03-09 Yi-Wen Chu Formulations with enhanced sn-38 solubility and oral absorption
JP7724358B2 (ja) 2021-10-15 2025-08-15 クンシャン シンユンダ バイオテック カンパニー， リミテッド 抗腫瘍薬を含む組成物、並びにその調製方法及びその使用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1395994A (en) 1972-08-23 1975-05-29 Delmar Chem Tocopherol derivative processes for making it and pharmaceutical compositions containing it
GB1409612A (en) 1973-09-13 1975-10-08 Ahrens G W Phenylpropyl-d-alpha-tocopherol-succinate the method for making the same and preparations
EP0008573A1 (en) 1977-12-16 1980-03-05 Nisshin Flour Milling Co., Ltd. Anti-tumor agent
JPS5484034A (en) * 1977-12-16 1979-07-04 Nisshin Flour Milling Co Ltd Anti-tumor agent
US4665204A (en) 1985-06-27 1987-05-12 Henkel Corporation Diester derivatives of tocopherol
US5610180A (en) 1988-01-29 1997-03-11 Virginia Commonwealth University Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
US5234695A (en) 1990-07-24 1993-08-10 Eastman Kodak Company Water dispersible vitamin E composition
DE59409377D1 (de) 1993-10-22 2000-06-29 Hexal Ag Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
CA2148148A1 (en) 1994-05-20 1995-11-21 Kazumi Ogata Tocopherol derivatives
DE4423915A1 (de) 1994-07-07 1996-01-11 Carl Heinrich Dr Weischer Derivate des Salazosulfapyridins, deren Herstellung und Verwendung als Arzneimittel
US5858398A (en) 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5945409A (en) 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
US5912078A (en) * 1996-05-02 1999-06-15 Milliken & Company Lubricant finish for textiles
ES2151277T3 (es) 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
AU735648B2 (en) * 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9715759D0 (en) 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations
EP1033372A4 (en) 1997-11-18 2000-10-04 Chugai Pharmaceutical Co Ltd COMPOSITIONS WITH ANTI-TUMOR ACTIVITY
US5917060A (en) 1997-12-17 1999-06-29 Basf Aktiengesellschaft Preparation of chromanyl derivatives
CA2315679A1 (en) 1997-12-24 1999-07-08 Senju Pharmaceutical Co., Ltd. Vitamin e derivatives
US6086915A (en) * 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
DK1115398T3 (da) 1998-09-23 2010-08-16 Res Dev Foundation Tocopheroler, tocotrienoler, andre chroman- og sidekædederivater og anvendelser deraf
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
KR20070058028A (ko) * 1999-05-24 2007-06-07 소너스파머슈티칼즈인코포레이티드 난용성 약물용 에멀젼 부형제
AU5871500A (en) * 1999-06-11 2001-01-02 Sydney Hyman Image making medium
WO2001022937A1 (en) * 1999-09-27 2001-04-05 Sonus Pharmaceuticals, Inc. Compositions of tocol-soluble therapeutics
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
WO2002076970A2 (en) * 2001-03-23 2002-10-03 Sonus Pharmaceuticals, Inc. Tocopherol succinate derivatives and compositions
US6774116B2 (en) * 2001-04-17 2004-08-10 Cryolife, Inc. Prodrugs via acylation with cinnamate
US6858227B1 (en) * 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
US6683194B2 (en) 2002-02-05 2004-01-27 Sonus Pharmaceuticals, Inc. Tocopherol derivatives

Also Published As

Publication number Publication date
BRPI0415858A (pt) 2007-01-09
US20060229359A1 (en) 2006-10-12
US20050096340A1 (en) 2005-05-05
US20070207196A1 (en) 2007-09-06
EP1682552B1 (en) 2010-06-30
AU2004285037A1 (en) 2005-05-12
TW200522978A (en) 2005-07-16
CA2543722A1 (en) 2005-05-12
KR20060110872A (ko) 2006-10-25
IL175158A0 (en) 2006-09-05
CA2543722C (en) 2011-01-04
US7223770B2 (en) 2007-05-29
WO2005042539A1 (en) 2005-05-12
EP1682552A1 (en) 2006-07-26
ATE472551T1 (de) 2010-07-15
AU2004285037B2 (en) 2010-07-22
JP2007509978A (ja) 2007-04-19

Similar Documents

Publication Publication Date Title
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
CY1107074T1 (el) Συνθεση εναντιομερων 4-αμινο-θαλιδομιδης
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
NO20026255L (no) Polymere micellesammensetninger
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
PL371736A1 (en) Method for administering glp-1 molecules
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
TW200603831A (en) Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
CY1109661T1 (el) 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
NO20063429L (no) Brusende oral opiat doseringsform
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
MX2007004765A (es) Compuestos y metodos que modulan la actividad de la trombopoyetina.
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
EA200501697A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей